Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Cymabay Therapeutics Inc | CBAY | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
32.46 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 7.2609 - 32.48 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 32.46 | USD |
Cymabay Therapeutics (CBAY) Options Flow Summary
Cymabay Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.72B | 114.72M | - | 31.07M | -105.37M | -0.92 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cymabay Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CBAY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 32.43 | 32.48 | 32.42 | 32.45 | 3,358,718 | 0.03 | 0.09% |
1 Month | 32.14 | 32.48 | 32.14 | 32.31 | 3,220,998 | 0.32 | 1.00% |
3 Months | 23.21 | 32.48 | 22.11 | 30.69 | 3,939,869 | 9.25 | 39.85% |
6 Months | 16.04 | 32.48 | 12.32 | 25.67 | 2,876,143 | 16.42 | 102.37% |
1 Year | 9.65 | 32.48 | 7.2609 | 19.82 | 2,425,430 | 22.81 | 236.37% |
3 Years | 4.81 | 32.48 | 1.6701 | 14.31 | 1,272,053 | 27.65 | 574.84% |
5 Years | 13.35 | 32.48 | 1.01 | 9.71 | 1,473,646 | 19.11 | 143.15% |
Cymabay Therapeutics Description
CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta. |